Associations of Vitamin D Receptor ApaI and Tru9I Polymorphisms With the Risk of Primary Open-angle Glaucoma

Overview

This study investigated whether vitamin D receptor gene polymorphism is altered in primary open-angle glaucoma subjects carrying the risk allele.Primary open-angle glaucoma patients and age-matched people in the Han population were enrolled. Vitamin D receptor polymorphic analysis was studied by polymerase chain reaction-restriction fragment length polymorphism technique.

Full Title of Study: “Associations of Vitamin D Receptor Polymorphisms With the Risk of Primary Open-angle Glaucoma”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Retrospective
  • Study Primary Completion Date: December 2014

Interventions

  • Other: Vitamin D receptor polymorphic analysis

Arms, Groups and Cohorts

  • primary open-angle glaucoma patients
    • vitamin D receptor polymorphic analysis was studied by real-time polymerase-chain reaction high resolution melting analysis in primary open-angle glaucoma patients.
  • randomly age-matched people
    • vitamin D receptor polymorphic analysis was studied by real-time polymerase-chain reaction high resolution melting analysis in randomly age-matched people.

Clinical Trial Outcome Measures

Primary Measures

  • gene polymorphisms of vitamin D receptor
    • Time Frame: 1 day visit

Participating in This Clinical Trial

Inclusion Criteria

  • intraocular pressure greater than 22 mmHg with two or more medications wide anterior chamber angle glaucomatous optic neuropathy (Glaucomatous optic nerve damage was defined as cup-to-disc ratio higher than 0.7 or focal loss of the nerve fiber layer (notch) associated with a consistent glaucomatous visual field defect) visual field loss consistent with optic nerve damage and visual fields were performed by using standard automated perimetry

Exclusion Criteria

  • the presence of any secondary glaucoma including exfoliation syndrome or a history of ocular trauma high myopia macular degeneration other ocular diseases a known history of systemic diseases and administration of vitamin D3 or other analog

Gender Eligibility: All

Minimum Age: 55 Years

Maximum Age: 65 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Lv Yingjuan
  • Collaborator
    • Tianjin Medical University Eye Hospital
  • Provider of Information About this Clinical Study
    • Sponsor-Investigator: Lv Yingjuan, department of ophthamology – Tianjin Medical University Eye Hospital

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.